Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the "Subscriber") of Resverlogix's Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the transaction, the Subscriber hold ...

Core Insights - Resverlogix Corp. has appointed Mr. Bradley Glass to its board of directors, bringing extensive legal and business experience to the company [1][3]. Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases, particularly in the field of epigenetics [4]. - The company is developing a new class of epigenetic therapies aimed at regulating disease-causing gene expression, with a focus on improving patients' lives affected by serious illnesses such as cardiovascular disease [5]. Strategic Partnerships - Resverlogix has partnered with EVERSANA™ to facilitate the rapid commercialization of its lead candidate, apabetalone, for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States [6].